Cargando…

Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting

BACKGROUND: In patients with a venous outflow obstruction following iliofemoral deep vein thrombosis stenting of the venous tract to prevent or alleviate postthrombotic syndrome is applied with increasing frequency. The impact of the quality of anticoagulant therapy with vitamin K antagonists (VKAs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Notten, Pascale, van Laanen, Jorinde H. H., Eijgenraam, Pieter, de Wolf, Mark A. F., Kurstjens, Ralph L. M., ten Cate, Hugo, ten Cate‐Hoek, Arina J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292674/
https://www.ncbi.nlm.nih.gov/pubmed/32548558
http://dx.doi.org/10.1002/rth2.12330
_version_ 1783546156146491392
author Notten, Pascale
van Laanen, Jorinde H. H.
Eijgenraam, Pieter
de Wolf, Mark A. F.
Kurstjens, Ralph L. M.
ten Cate, Hugo
ten Cate‐Hoek, Arina J.
author_facet Notten, Pascale
van Laanen, Jorinde H. H.
Eijgenraam, Pieter
de Wolf, Mark A. F.
Kurstjens, Ralph L. M.
ten Cate, Hugo
ten Cate‐Hoek, Arina J.
author_sort Notten, Pascale
collection PubMed
description BACKGROUND: In patients with a venous outflow obstruction following iliofemoral deep vein thrombosis stenting of the venous tract to prevent or alleviate postthrombotic syndrome is applied with increasing frequency. The impact of the quality of anticoagulant therapy with vitamin K antagonists (VKAs) on the development of in‐stent thrombosis is currently unknown. OBJECTIVES: To determine the association between the quality of postinterventional VKA treatment and the occurrence of in‐stent thrombosis. METHODS: Seventy‐nine patients with iliofemoral and/or caval venous stent placement for obstruction of the venous outflow were included in this study. All patients received postinterventional VKA. The quality of VKA anticoagulant therapy was expressed as the time within therapeutic range (TTR) calculated using the linear interpolation method and as the proportion of International Normalized Ratio (INR) values < 2.0. In‐stent thrombosis was assessed by the use of duplex ultrasound. Survival analysis (Kaplan‐Meier curves, Cox regression) was used to analyze the data. RESULTS: In‐stent thrombosis developed in 16 patients (20.3%). The total population had a mean TTR of 64.0% (±19.0) and a mean proportion of INR values < 2.0 of 11.6% (±12.0). Overall, a TTR < 49.9% was associated with an increased risk of in‐stent thrombosis. The multivariable adjusted analysis showed a hazard ratio (HR) of 0.96 (95% confidence interval [CI], 0.92‐0.99; P = .02) per 1% increase in TTR. The proportion of INR values < 2.0 had no significant association with the occurrence of in‐stent thrombosis: HR 0.98 (95% CI, 0.91‐1.06; P = .66). CONCLUSIONS: We conclude that the quality of anticoagulant treatment reflected in the TTR following a venous stenting procedure is an important independent determinant for the risk of in‐stent thrombosis. The role of anticoagulant treatment for the prevention of in‐stent thrombosis following stenting procedures therefore merits further research.
format Online
Article
Text
id pubmed-7292674
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72926742020-06-15 Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting Notten, Pascale van Laanen, Jorinde H. H. Eijgenraam, Pieter de Wolf, Mark A. F. Kurstjens, Ralph L. M. ten Cate, Hugo ten Cate‐Hoek, Arina J. Res Pract Thromb Haemost Original Article: Thrombosis BACKGROUND: In patients with a venous outflow obstruction following iliofemoral deep vein thrombosis stenting of the venous tract to prevent or alleviate postthrombotic syndrome is applied with increasing frequency. The impact of the quality of anticoagulant therapy with vitamin K antagonists (VKAs) on the development of in‐stent thrombosis is currently unknown. OBJECTIVES: To determine the association between the quality of postinterventional VKA treatment and the occurrence of in‐stent thrombosis. METHODS: Seventy‐nine patients with iliofemoral and/or caval venous stent placement for obstruction of the venous outflow were included in this study. All patients received postinterventional VKA. The quality of VKA anticoagulant therapy was expressed as the time within therapeutic range (TTR) calculated using the linear interpolation method and as the proportion of International Normalized Ratio (INR) values < 2.0. In‐stent thrombosis was assessed by the use of duplex ultrasound. Survival analysis (Kaplan‐Meier curves, Cox regression) was used to analyze the data. RESULTS: In‐stent thrombosis developed in 16 patients (20.3%). The total population had a mean TTR of 64.0% (±19.0) and a mean proportion of INR values < 2.0 of 11.6% (±12.0). Overall, a TTR < 49.9% was associated with an increased risk of in‐stent thrombosis. The multivariable adjusted analysis showed a hazard ratio (HR) of 0.96 (95% confidence interval [CI], 0.92‐0.99; P = .02) per 1% increase in TTR. The proportion of INR values < 2.0 had no significant association with the occurrence of in‐stent thrombosis: HR 0.98 (95% CI, 0.91‐1.06; P = .66). CONCLUSIONS: We conclude that the quality of anticoagulant treatment reflected in the TTR following a venous stenting procedure is an important independent determinant for the risk of in‐stent thrombosis. The role of anticoagulant treatment for the prevention of in‐stent thrombosis following stenting procedures therefore merits further research. John Wiley and Sons Inc. 2020-04-08 /pmc/articles/PMC7292674/ /pubmed/32548558 http://dx.doi.org/10.1002/rth2.12330 Text en © 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Article: Thrombosis
Notten, Pascale
van Laanen, Jorinde H. H.
Eijgenraam, Pieter
de Wolf, Mark A. F.
Kurstjens, Ralph L. M.
ten Cate, Hugo
ten Cate‐Hoek, Arina J.
Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting
title Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting
title_full Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting
title_fullStr Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting
title_full_unstemmed Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting
title_short Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting
title_sort quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting
topic Original Article: Thrombosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292674/
https://www.ncbi.nlm.nih.gov/pubmed/32548558
http://dx.doi.org/10.1002/rth2.12330
work_keys_str_mv AT nottenpascale qualityofanticoagulanttherapyandtheincidenceofinstentthrombosisaftervenousstenting
AT vanlaanenjorindehh qualityofanticoagulanttherapyandtheincidenceofinstentthrombosisaftervenousstenting
AT eijgenraampieter qualityofanticoagulanttherapyandtheincidenceofinstentthrombosisaftervenousstenting
AT dewolfmarkaf qualityofanticoagulanttherapyandtheincidenceofinstentthrombosisaftervenousstenting
AT kurstjensralphlm qualityofanticoagulanttherapyandtheincidenceofinstentthrombosisaftervenousstenting
AT tencatehugo qualityofanticoagulanttherapyandtheincidenceofinstentthrombosisaftervenousstenting
AT tencatehoekarinaj qualityofanticoagulanttherapyandtheincidenceofinstentthrombosisaftervenousstenting